Correlation Engine 2.0
Clear Search sequence regions


  • after treatment (1)
  • breast (3)
  • caelyx (2)
  • cancer (2)
  • cell (9)
  • cholesterol (1)
  • colon cancer (2)
  • doxorubicin (13)
  • drug carriers (2)
  • glycols (2)
  • had (1)
  • humans (1)
  • intracellular (2)
  • lip (8)
  • MRP1 (2)
  • nitric oxide (5)
  • ovary (2)
  • ovary tumors (1)
  • Pgp (4)
  • Pgp 1 (1)
  • Sizes of these terms reflect their relevance to your search.

    In this work we prepared and characterized two liposomal formulations of a semisynthetic nitric oxide (NO)-releasing doxorubicin (Dox), called nitrooxy-Dox (NitDox), which we previously demonstrated to be cytotoxic in Dox-resistant human colon cancer cells. Liposomes with 38.2% (Lip A) and 19.1% (Lip B) cholesterol were synthesized: both formulations had similar size and zeta potential values and caused the same intracellular distribution of free NitDox, but Lip B accumulated and released NitDox more efficiently. In Dox-resistant human colon cancer cells, Lip A and Lip B exhibited a more favorable kinetics of drug uptake and NO release, and a stronger cytotoxicity than Dox and free NitDox. While Caelyx, one of the liposomal Dox formulations approved for breast and ovary tumors treatment, was ineffective in Dox-resistant breast/ovary cancer cells, Lip B, and to a lesser extent Lip A, still exerted a significant cytotoxicity in these cells. This event was accompanied in parallel by a higher release of NO, which caused nitration of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two transporters involved in Dox efflux, and impaired their pump activity. By doing so, the efflux kinetics of Dox after treatment with Lip B was markedly slowed down and the intracellular accumulation of Dox was increased in breast and ovary drug-resistant cells. We propose these liposomal formulations of NitDox as new tools with a specific indication for tumors overexpressing Pgp and MRP1.

    Citation

    Isabella Pedrini, Elena Gazzano, Konstantin Chegaev, Barbara Rolando, Alessandro Marengo, Joanna Kopecka, Roberta Fruttero, Dario Ghigo, Silvia Arpicco, Chiara Riganti. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. Molecular pharmaceutics. 2014 Sep 2;11(9):3068-79

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 25057799

    View Full Text